Klaus Schmierer
Queen Mary University of London
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Klaus Schmierer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:47 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05418010 · Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)Queen Mary University of London · recruiting · Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:47 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- 386 citationsRCR 10.1
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.JAMA Neurol · 2017206 citationsRCR 7.9
- Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.Lancet Neurol · 2016151 citationsRCR 6.3
- 101 citationsRCR 2.6
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.Mult Scler · 201256 citationsRCR 1.7
- 49 citationsRCR 1.5
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis.J Neurol · 201138 citationsRCR 1.2
- Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.Mult Scler Relat Disord · 201728 citationsRCR 1.2
- A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study.Mult Scler Relat Disord · 201828 citationsRCR 1.0
- Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.Front Immunol · 202514 citationsRCR 4.6